Coffee: Live Longer And Prosper?

According to a report in the “Annals of Internal Medicine,” recent research notes that drinking hot coffee could be connected to a much lower possibility of death by such medical problems as stroke or heart disease. Previous research studies have made similar observations about coffee possibly lengthening one’s life. As a matter of fact, the particular health limitations and potential health benefits have been studied for a long time now. Read more at PRNewswire about Organo Gold.

The most recently published study included over 185,000 U.S. residents. The research subjects included a mix of African-Americans, European-Americans, Latin-Americans, and Japanese Americans. The study revealed that the subjects who enjoyed coffee, be it caffeinated or decaffeinated, appeared less likely to succumb to cancer, diabetes, stroke, heart disease, and kidney disease.


The research subjects reported the results of their individual coffee drinking behavior and, in addition, provided personal five-year updates. Subjects who noted that they enjoyed two to three cups of coffee daily had an 18 percent less probability of expiring as compared to those who didn’t drink coffee over the entire 16-year test period. The latest European studies included over 520,000 individuals from 10 countries. The research indicated that people who drank several cups of coffee on a daily basis were less likely to die than people who never, ever drank coffee. None of the researchers, however, were able to actually to prove a true causal relationship.

Organo Gold

Organo Gold is a business run by famous entrepreneur Bernardo Chua. Chua is the company founder and the CEO (chief executive officer). The company was launched in 2008.

This international gourmet coffee vendor markets a product line of tea, coffee, nutraceuticals, and additional items. They all contain the company’s key ingredient, Ganoderma lucidum. Ganoderma lucidum is a fungus or mushroom grown in Asia that’s used as an antioxidant. Organo Gold is also available at

Leave a Reply

Name *
Email *